XOMA Royalty Corporation Annual report [Section 13 and 15(d), not S-K Item 405]

Commitments and Contingencies - Contingent Consideration (Details)

Commitments and Contingencies - Contingent Consideration (Details) - USD ($) $ in Thousands			1 Months Ended		3 Months Ended		12 Months Ended
	Jun. 21, 2023	Oct. 06, 2021	Mar. 31, 2025	Jan. 31, 2024	Dec. 31, 2024	Mar. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Sep. 30, 2024	Apr. 03, 2024
Commitments And Contingencies
Contingent consideration under RPAs, AAAs, and CPPAs					$ 3,000		$ 3,000	$ 7,000
Payments of consideration under RPAs, AAAs and CPPAs							53,000	14,650
Short-term royalty and commercial payment receivables under the cost recovery method					413		413	14,215
Long-term royalty and commercial payment receivables under the cost recovery method					55,936		55,936	57,952
Exarafenib milestone contingent consideration					3,214		3,214
Affitech \| Sales-based milestones \| Subsequent Event
Commitments And Contingencies
Payments of consideration under RPAs, AAAs and CPPAs			$ 6,000
Assignment and Assumption Agreement and Royalty Purchase Agreement \| LadRx
Commitments And Contingencies
Payments of consideration under RPAs, AAAs and CPPAs	$ 5,000			$ 1,000	1,000
Short-term royalty and commercial payment receivables under the cost recovery method					400		400
Long-term royalty and commercial payment receivables under the cost recovery method	6,000
Assignment and Assumption Agreement and Royalty Purchase Agreement \| LadRx \| Regulatory milestones
Commitments And Contingencies
Contingent consideration under RPAs, AAAs, and CPPAs	$ 1,000				0	$ 0	0	1,000
Payments of consideration under RPAs, AAAs and CPPAs				$ 1,000			1,000
Assignment and Assumption Agreement and Royalty Purchase Agreement \| LadRx \| Sales-based milestones
Commitments And Contingencies
Contingent consideration under RPAs, AAAs, and CPPAs					0		0		$ 1,000
Payments of consideration under RPAs, AAAs and CPPAs					1,000
Long-term royalty and commercial payment receivables under the cost recovery method									$ 1,000
Commercial Payment Purchase Agreement \| Affitech
Commitments And Contingencies
Payments of consideration under RPAs, AAAs and CPPAs		$ 6,000
Commercial Payment Purchase Agreement \| Affitech \| Regulatory milestones
Commitments And Contingencies
Contingent consideration under RPAs, AAAs, and CPPAs		$ 8,000
Commercial Payment Purchase Agreement \| Affitech \| Sales-based milestones, first and second
Commitments And Contingencies
Contingent consideration under RPAs, AAAs, and CPPAs						0		6,000
Payments of consideration under RPAs, AAAs and CPPAs						6,000
Long-term royalty and commercial payment receivables under the cost recovery method								$ 6,000
Commercial Payment Purchase Agreement \| Affitech \| Sales-based milestones, third
Commitments And Contingencies
Contingent consideration under RPAs, AAAs, and CPPAs					3,000	3,000	3,000
Short-term royalty and commercial payment receivables under the cost recovery method						$ 3,000
CVR Agreement \| Kinnate CVR holders
Commitments And Contingencies
Exarafenib milestone contingent consideration					$ 3,200		$ 3,200			$ 2,900